Roles of the actin cytoskeleton in aging and age-associated diseases.

The objective of this article is to revisit the current understanding of the roles played by the actin cytoskeleton in aging, and to review the opportunities and challenges for transition of basic research to intervention development. It is hoped that, with the snapshot of evidence regarding changes in actin dynamics with advanced age, insights on anti-aging medicine can be attained for future research. PMID: 31968269 [PubMed - as supplied by publisher]
Source: Ageing Research Reviews - Category: Genetics & Stem Cells Authors: Tags: Ageing Res Rev Source Type: research

Related Links:

Glioblastoma multiforme (GBM) is a malignant brain tumor with a poor prognosis resulting from tumor resistance to anticancer therapy and a high recurrence rate. Compelling evidence suggests that this is driven by subpopulations of cancer stem cells (CSCs) with tumor-initiating potential. ABC subfamily B member 5 (ABCB5) has been identified as a molecular marker for distinct subsets of chemoresistant tumor-initiating cell populations in diverse human malignancies. In the current study, we examined the potential role of ABCB5 in growth and chemoresistance of GBM. We found that ABCB5 is expressed in primary GBM tumors, in whi...
Source: Journal of Biological Chemistry - Category: Chemistry Authors: Tags: Cell Biology Source Type: research
A new double-contrast MRI technique in development could help the modality...Read more on AuntMinnie.comRelated Reading: COVID-19 neuro findings marked by mental status, stroke fMRI-based machine learning helps predict coma outcomes ISMRM annual meeting goes virtual MRI illuminates neurologic manifestations of COVID-19 MRI could help predict efficacy of stem cell therapy
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
             Basel, 28 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced European Medicines Agency (EMA) approval of a new, shorter two-hour OCREVUS ® (ocrelizumab) infusion time, dosed twice yearly, for relapsing or primary progressive multiple sclerosis (MS). The approval is based on a positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP).“The approval of a shorter, two-hour infusion time for OCREVUS in Europe, dosed twice yearly, will further improve the treatment experience for patients while als...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
Publication date: Available online 26 May 2020Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Saten Hovhannisyan, Julieta Hoveyan, Tigran Aghabekyan, Gevorg Tamamyan
Source: Hematology Oncology and Stem Cell Therapy - Category: Cancer & Oncology Source Type: research
Stochastic mutational damage to nuclear DNA occurs constantly in the body, and near all of it is quickly repaired. Most unrepaired damage occurs in DNA that isn't used, or the change has only has a small effect on cell metabolism, or occurs in a somatic cell that will replicate only a limited number of times. When mutations occur in stem cells or progenitor cells, however, they can spread widely through tissue, producing a pattern of mutations known as somatic mosaicism. It is thought that this can contribute to the progression of aging via a slowly growing disarray of cellular metabolism, particularly through the spread o...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs
In this study, researchers investigated if specific targeting of CD133+ glioblastoma with cutting-edge immunotherapy drugs could eradicate the most aggressive subpopulation of cells in the tumor. They also looked at the safety of CD133-targeting therapies on normal, non-cancerous human stem cells including hematopoietic stem cells which create blood cells and progenitor cells which can form one or more kinds of cells.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Conclusion: Overall, these data indicate that IL31RA promotes basal-like breast cancer progression and metastasis, suggesting that targeting of IL-31/IL31RA axis might be beneficial to treatment of BLBC.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Chimeric antigen receptor-modified (CAR) T cells targeting CD19 have revolutionized the treatment of relapsed or refractory aggressive B-cell lymphomas, and their use has increased the cure rate for these cancers from 10 to 40%. Two second-generation anti-CD19 CAR T-cell products, axicabtagene ciloleucel and tisagenlecleucel, have been approved for use in patients, and the approval of a third product, lisocabtagene maraleucel, is expected in 2020. The commercial availability of the first two products has facilitated the development of real-world experience in treating relapsed or refractory aggressive B-cell lymphomas, she...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
DiscussionIf the trial demonstrates non-inferiority of early switching to oral antibiotics, with potential benefits for patient quality of life and resource savings, this finding will have significant implications for the routine clinical management of those with low-risk neutropenic sepsis.Trial registrationISRCTN: 84288963. Registered on the 1 July 2015.https://doi.org/10.1186/ISRCTN84288963.EudraCT: 2015-002830-35.
Source: Trials - Category: Research Source Type: clinical trials
Impaired immune reconstitution after allogeneic hematopoietic stem cell transplantation (HSCT) contributes to increased risk of cancer relapse and infection resulting in significant morbidity and mortality. Unfortunately, effective strategies to functionally assess the quality of immune reconstitution are still missing. Quantification of in vivo replication of the ubiquitous, non-pathogenic virus Torque Teno Virus (TTV) has been reported in small series as a test to functionally evaluate the quality of post-transplant immune reconstitution. In the present study, we analyzed by quantitative PCR TTV titers in plasma samples ...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
More News: Brain | Cancer | Cancer & Oncology | Genetics | Neurology | Neuroscience | Science | Stem Cell Therapy | Stem Cells